Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
TITAN PHARMACEUTICALS INC (TTNP)
|
Add to portfolio |
|
|
|
| Price: |
$2.44
| | Metrics |
| OS: |
15.0
|
M
| |
|
|
| Market cap: |
$36.6
|
M
| |
|
|
|
Net cash:
|
$105
|
k
| |
$0.01
|
per share
|
|
EV:
|
$36.5
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($9.9)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.6 | 1.5 | 4.8 | 2.6 | 6.6 | 0.2 | 15.1 | 1.7 |
| Revenue growth | -63.5% | -68.5% | 85.7% | -60.6% | 2978.1% | -98.6% | 801.6% | -54.2% |
| Cost of goods sold | -10.9 | 0.2 | 0.5 | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 |
| Gross profit | 11.4 | 1.3 | 4.4 | 2.6 | 6.1 | 0.2 | 15.1 | 1.7 |
| Gross margin | 2051.0% | 87.0% | 90.2% | 100.0% | 91.9% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | | | | | 6.9 | 5.1 | 4.6 | |
| Research and development | 4.8 | 5.7 | 5.9 | 5.1 | 7.5 | 9.6 | 6.1 | 4.7 |
| General and administrative | 6.0 | 5.0 | 5.8 | 5.4 | | | | 3.8 |
| EBIT | -10.2 | -9.4 | -7.4 | -7.9 | -8.3 | -14.5 | 4.3 | -6.8 |
| EBIT margin | -1824.1% | -613.0% | -151.9% | -302.3% | -124.9% | -6745.1% | 28.8% | -404.5% |
| Pre-tax income | -10.2 | -8.8 | -7.4 | -7.5 | -9.3 | -14.3 | 5.1 | -11.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -10.2 | -8.8 | -7.4 | -7.5 | -9.3 | -14.3 | 5.1 | -11.3 |
| Net margin | -1832.3% | -575.1% | -153.1% | -287.5% | -140.6% | -6654.4% | 34.1% | -675.0% |
| |
| Diluted EPS | ($0.76) | ($0.90) | ($1.96) | ($9.78) | ($1.64) | ($4.04) | $1.44 | ($0.56) |
| Shares outstanding (diluted) | 13.4 | 9.7 | 3.8 | 0.8 | 5.7 | 3.5 | 3.6 | 20.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|